Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-071 single-dose pharmacology study in pediatric type 2 diabetes
jRCT2080223964Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of luseogliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Taisho Pharmaceutical. Primary endpoints: Pharmacokinetics of unchanged luseogliflozin and Pharmacokinetics of metabolites. Started Jul 2018; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080223964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223964.